Insider Cluster (3 insiders) ·Filed Apr 2, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago
Insider cluster: 3 insiders, $0.4M total
Actionable Insight • Neutral

The sales are small relative to company size and likely part of pre-arranged 10b5-1 plans following option exercises. Not a material negative signal. Watch for future filings to see if selling continues beyond this cluster.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
UTHR ▼ -3.54% at T+60d
NEUTRAL call ✗ call lost -3.54% · α vs SPY -16.53% · entry $564.94 → $544.92
Entry anchored
Apr 1, 03:59 PM ET
via exchange tick
T+1d
-1.57%
call -1.57% · α -2.05%
$556.07
settled 6mo ago
T+5d
+1.13%
call +1.13% · α -2.49%
$571.32
settled 6mo ago
T+20d
+1.13%
call +1.13% · α -8.74%
$571.35
settled 5mo ago
T+60d
-3.54%
call -3.54% · α -16.53%
$544.92
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Three top executives at United Therapeutics — the CEO, CFO, and General Counsel — sold a combined $376K in shares over a 7-day window, following the exercise of stock options. The sales represent less than 0.0015% of the company's $24.8B market cap and appear to be part of pre-planned, non-discretionary transactions following option exercises.

Key Financial Metrics

Direction
selling
Total Value
$376.0K
Insiders
3

Key Facts

  • CEO Martine Rothblatt sold $21.7K, CFO James Edgemon sold $66.3K, and General Counsel Paul Mahon sold $288K in open-market transactions.
  • All sales followed the exercise of stock options, with significant non-cash derivative exercises totaling over $5.4M in option value realized.
  • Total dollar value of open-market sales ($376K) is only 0.0015% of the company's $24.8B market cap.
  • Sales occurred at prices between $551.86 and $560.30 per share.

Financial Impact

$376,000 in net insider selling

insider ownershipmarket sentiment (minor)

Risk Factors

  • Perception of insider pessimism if media or retail investors misinterpret routine transactions.
  • Potential for increased scrutiny if similar clusters recur in the near term.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1775680472985
91 reports for UTHR
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +5.53%Feb 25, 2026
Filters
Rows
Reports for UTHR — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 2/10
$500.35 $497.31▼ −0.61%▼ −2.72%$571.38 (+14.20%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$497.11 $494.63▼ −0.50%▼ −0.28%$571.38 (+14.94%)
Sep 10, 2026
22d ago
Insider Cluster
MIXED ★ 4/10
$503.86 $497.27▼ −1.31%▼ −0.81%$571.38 (+13.40%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$506.82 $498.48▼ −1.65%▼ −0.99%$571.38 (+12.74%)
Sep 4, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$487.61 $502.70▲ +3.09%▲ +4.30%$571.38 (+17.18%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$488.16 $497.11▲ +1.83%▲ +2.98%$571.38 (+17.05%)
Aug 28, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$515.46 $487.61▼ −5.40%▼ −5.51%$571.38 (+10.85%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$527.91 $492.02▼ −6.80%▼ −6.03%$571.38 (+8.23%)
Aug 26, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$516.68 $492.02▼ −4.77%▼ −4.65%$571.38 (+10.59%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$516.68 $492.02▼ −4.77%▼ −4.65%$571.38 (+10.59%)
Showing 10 of 91

US Market Status

Market Open — Closes in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 8, 2026